Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000902664-25-001007
Filing Date
2025-02-14
Accepted
2025-02-14 14:35:21
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 8987
2 JOINT FILING AGREEMENT p25-0496exhibit99_1.htm EX-99.1 3318
  Complete submission text file 0000902664-25-001007.txt   14087
Mailing Address 545 FIFTH AVENUE, SUITE 1400 NEW YORK NY 10017
Business Address 545 FIFTH AVENUE, SUITE 1400 NEW YORK NY 10017 212-220-9226
Applied Therapeutics, Inc. (Subject) CIK: 0001697532 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-91017 | Film No.: 25626906
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 632 BROADWAY SUITE 602 NEW YORK NY 10012
Business Address 632 BROADWAY SUITE 602 NEW YORK NY 10012 6469894000
Vestal Point Capital, LP (Filed by) CIK: 0001974915 (see all company filings)

EIN.: 922296021 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G